Nebivolol Lannacher (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Lannacher, is a beta blocker presented as a tablet for oral use. It treats hypertension and is indicated for adult patients requiring blood pressure control.

GNH USA supplies Nebivolol Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular therapy. It helps manage blood pressure and related conditions. - Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. - Heart failure with reduced ejection fraction: improves ventricular function and symptoms. - Elderly patients with hypertension: provides effective control with a favorable tolerability profile.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nasal congestion or rhinorrhea. - Bradycardia: heart rate below 60 bpm. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute hypotension with syncope. - Bronchospasm in patients with reactive airway disease. - Hepatic injury indicated by elevated transaminases. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Cardiovascular collapse in overdose situations.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly. - Blood pressure monitoring: check regularly to ensure therapeutic target is reached. - Heart rate assessment: observe for bradycardia, especially in patients with conduction disorders. - Asthma or COPD caution: avoid in uncontrolled reactive airway disease. - Liver function: evaluate baseline hepatic enzymes and monitor during treatment. - Renal impairment: adjust dose in severe renal dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects may cause severe bradycardia. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): can markedly depress cardiac conduction. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may enhance antihypertensive effect, requiring blood pressure monitoring. - Diuretics: risk of excessive hypotension or electrolyte imbalance. - NSAIDs: may attenuate antihypertensive response. - Anti‑arrhythmic agents (e.g., amiodarone): may increase risk of conduction disturbances.